Publications by authors named "David Santos-Lazaro"
To systematize published laboratory methods to inactivate Mycobacterium tuberculosis (MTB) and to describe their effectiveness. We carried out a review of the scientific literature to identify the publications that reported methods for the inactivation of MTB, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses recommendations. The search addressed inactivation methodologies used in Public health laboratories for the treatment of biological material and only included studies reporting the efficacy of the method.
View Article and Find Full Text PDFArticle Synopsis
- Whole Genome Sequencing (WGS) proves to be an effective method for detecting drug resistance and transmission clusters in multidrug-resistant tuberculosis (TB) in Peru, with a study analyzing 140 strains.
- WGS showed a high agreement (96.5%) with traditional testing methods (BACTEC MGIT) for detecting resistance to seven key anti-TB drugs, although some traditional results were invalid for 10-17% of cases.
- This method yielded quick results, averaging 11.5 days for WGS compared to 28.6-52.6 days for routine processes, and revealed that most strains belonged to a single lineage with low transmission cluster rates.
Background: Tuberculosis (TB) is a communicable, preventable and curable disease caused by the bacterium Mycobacterium tuberculosis (MTB). Peru is amongst the 30 countries with the highest burden of multidrug-resistant tuberculosis (MDR-TB) worldwide. In the fight against drug-resistant tuberculosis, the UKMYC6 microdilution plate was developed and validated by the CRyPTIC project.
View Article and Find Full Text PDFArticle Synopsis
- - The study aimed to analyze the genetic structure of drug-resistant Mycobacterium tuberculosis strains in Peru from 2011 to 2015 using genetic haplotypes from a line probe assay.
- - Researchers examined 6,589 samples and identified key mutations associated with drug resistance, finding high frequencies in specific genetic markers for rifampicin and isoniazid resistance.
- - The results revealed a high diversity of drug-resistant strains, particularly in Lima and Callao, indicating a significant presence of globally common genetic markers linked to treatment resistance.
Article Synopsis
- * New anti-TB drugs like bedaquiline (BDQ), delamanid (DLM), and pretomanid (PTM) have been approved for treating drug-resistant TB, but there are increasing cases of resistance developing against these drugs.
- * The study examined over 33,000 TB isolates to identify genetic variations linked to resistance, highlighting significant mutations and their potential impact on treatment effectiveness, ultimately aiming to enhance understanding and improve outcomes for TB management.
Article Synopsis
- Peru has the highest rate of multidrug-resistant tuberculosis (TB) in the Americas, with a significant rise in extensively drug-resistant TB (XDR-TB) cases since 1999.
- The study focused on genomic characterization of 68 XDR-TB strains from patients diagnosed between 2011 and 2015, primarily from densely populated areas in Lima and Callao, revealing that the majority belonged to the Euro-American lineage.
- Whole genome sequencing showed 90% of strains had high-confidence resistance mutations, highlighting WGS's ability to identify drug resistance, track transmission, and understand the evolution of XDR-TB strains in Peru.